Life Sciences & Medicine Active Updated Jul 7, 2026
GLP-1 drugs, beyond weight loss
The GLP-1 drugs are turning out to change mood, behavior and the brain's relationship with food, not just body weight, as coverage expands to older adults.
The story so far
-
Jul 7, 2026 Latest
Cleveland Clinic researchers analyzed records from 2,133 people with type 2 diabetes and peripheral artery disease and found those prescribed GLP-1 receptor agonists like semaglutide had a 48 percent lower risk of major amputation, a 37 percent lower risk of minor amputation, and a 36 percent lower risk of circulation-restoring procedures over five years, compared to a matched metformin group. They were also 26 percent less likely to die from any cause. Whether the benefit comes from weight loss, blood sugar control, or a direct effect on blood vessel walls remains unclear.
-
Jun 21, 2026
A review found the drugs work well for most people but not all, with a minority seeing little benefit.
-
Jun 17, 2026
Reporting described GLP-1 drugs quieting the constant mental chatter about food known as food noise, as Medicare coverage began for adults 65 and older.
-
Jun 14, 2026
Research found GLP-1 weight-loss drugs change bodies in unexpected ways, including measurable drops in daily step counts.
This story moves with the morning letter.
When this arc advances, the timeline above grows the same morning. One short, warm letter with the day's real progress in science, medicine and beyond. Free, every day.
Free forever, no spam. One click to unsubscribe, and we never sell your email.